RT Journal Article
SR Electronic
T1 Nonutility of procalcitonin for diagnosing bacterial pneumonia in COVID-19
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.03.29.22272960
DO 10.1101/2022.03.29.22272960
A1 Cohen, Avi J.
A1 Glick, Laura R.
A1 Lee, Seohyuk
A1 Kunitomo, Yukiko
A1 Tsang, Derek A.
A1 Pitafi, Sarah
A1 Toro, Patricia Valda
A1 Zhang, Ethan
A1 Datta, Rupak
A1 Dela Cruz, Charles S.
A1 Gautam, Samir
YR 2022
UL http://medrxiv.org/content/early/2022/04/05/2022.03.29.22272960.abstract
AB Patients hospitalized with COVID-19 are at significant risk for superimposed bacterial pneumonia. However, diagnosing superinfection is challenging due to its clinical resemblance to severe COVID-19. We therefore evaluated whether the immune biomarker, procalcitonin, could facilitate the diagnosis of bacterial superinfection. To do so, we identified 185 patients with severe COVID-19 who underwent lower respiratory culture; 85 had superinfection. Receiver operating characteristic curve analysis showed that procalcitonin at the time of culture was incapable of distinguishing patients with bacterial infection (AUC, 0.52). We conclude that static measurement of procalcitonin does not aid in the diagnosis of superinfection in severe COVID-19.Competing Interest StatementSamir Gautam, MD PhD: Advisory Board, AstraZenecaFunding StatementThis study was funded by the following: T32 from the National Institute of Allergy and Infectious Diseases (AI007517), Claude D. Pepper Older Americans Independence Center at Yale (P30AG021342) and Yale Center for Clinical Investigation Scholar Award to RD; U.S. Department of Veterans Affairs Merit award (BX004661), U.S. Department of Defense (PR181442), and U19 from the National Heart, Lung, and Blood Institute (AI089992-09S2) to CSD. T32 from the National Heart, Lung, and Blood Institute (HL007778), F32 from the National Heart, Lung, and Blood Institute (HL154641), Cystic Fibrosis Foundation Fellowship GAUTAM20D0, Parker B. Francis Fellowship, Robert E. Leet and Clara Guthrie Patterson Trust Mentored Research Award, and Yale Center for Clinical Investigation Scholar Award to SG.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Yale University Institutional Review Board gave ethical approval for this work (approval #2000023067).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors.